Streamlining Dermatology Cohere Health Prior Authorizations

Navigating prior authorizations for dermatology patients, particularly those managed by Cohere Health, demands a specialized approach to ensure timely access to critical treatments and procedures.

Revenue cycle directors and prior authorization coordinators face unique complexities in dermatology, from high-cost biologics to nuanced surgical procedures. When payers like Humana and Geisinger Health Plan leverage AI-driven platforms such as Cohere Health, efficient data exchange and precise clinical documentation become paramount. Klivira provides the automation layer to bridge these gaps, ensuring your dermatology practice maintains optimal workflow efficiency.

The Nuance of Dermatology PA with Cohere Health

Dermatology prior authorizations are inherently complex, driven by high-cost biologics for conditions like psoriasis and atopic dermatitis, alongside specific procedures such as Mohs micrographic surgery. When these requests are routed through AI-driven platforms like Cohere Health, which serves payers such as Humana and Geisinger Health Plan, the need for accurate, evidence-based submissions is amplified. Klivira integrates directly to ensure that the clinical rationale aligns with payer requirements, minimizing friction.

Common Prior Authorization Triggers in Dermatology

Biologics for psoriasis and psoriatic arthritis (e.g., Dupixent, Cosentyx, Tremfya, Skyrizi, Humira)
Biologics for atopic dermatitis and hidradenitis suppurativa
Mohs micrographic surgery for non-melanoma skin cancers
Advanced skin cancer treatments, including immunotherapy
Home phototherapy for chronic conditions

Documentation Excellence for Cohere Health Submissions

Successful prior authorization submissions to platforms like Cohere Health hinge on meticulous documentation that adheres to established clinical guidelines. For dermatology, this often means strict adherence to AAD Clinical Guidelines for biologics, requiring detailed disease severity scores (PASI, BSA, EASI, SCORAD), trials of prior topical or systemic therapies, and pre-biologic screenings. For Mohs surgery, conformance to AAD Appropriate Use Criteria (AUC) is critical for approval.

Navigating Payer Policies and Workflow Constraints

Dermatology practices encounter specific workflow challenges, including periodic re-authorization cycles for chronic biologic treatments and the distinction between medical and pharmacy benefit routing for self-administered versus clinic-infused medications. Cohere Health's platform streamlines payer-side review, making it essential for providers to submit complete X12 278 or ePA requests that anticipate these requirements. Klivira's system is designed to manage these nuances, ensuring seamless communication and compliance.

Klivira's Solution for Dermatology Prior Authorizations

Klivira's platform provides a robust solution for managing dermatology prior authorizations, particularly those processed by Cohere Health. We incorporate AAD-guideline-aware step-therapy logic for biologics, validate Mohs surgery against AUC, and automate periodic re-authorization workflows. By routing requests correctly based on medical-vs-pharmacy benefit, Klivira helps dermatology practices reduce manual effort and improve approval rates, enhancing revenue cycle performance.

EMR Integration and Data Exchange Efficiency

Seamless EMR integration is critical for efficient prior authorization workflows. Klivira connects with major EMR systems to extract necessary clinical data, such as diagnosis codes, severity scores, and treatment history, directly for submission to Cohere Health via ePA or X12 278 transactions. Leveraging standards like SMART on FHIR and the Da Vinci PAS implementation guide, this direct data exchange minimizes manual entry, reduces errors, and accelerates the entire prior authorization process, ensuring that patient care is not delayed.

Frequently asked questions

How does Klivira handle re-authorizations for chronic dermatology conditions?

Klivira automates the tracking and submission of periodic re-authorizations for chronic biologic treatments in dermatology. Our system flags upcoming re-authorization dates and pre-populates forms with updated clinical information, ensuring continuity of care and preventing treatment delays.

What specific guidelines does Klivira use for dermatology PA?

Klivira's platform incorporates logic based on AAD Clinical Guidelines for conditions like psoriasis and atopic dermatitis, and AAD Appropriate Use Criteria for Mohs surgery. This ensures that submitted documentation aligns with evidence-based standards, increasing the likelihood of approval from platforms like Cohere Health.

How does Klivira differentiate between medical and pharmacy benefit for dermatology biologics?

Klivira's system is configured to correctly route prior authorization requests based on whether a biologic is self-injected (pharmacy benefit) or administered in a clinic (medical benefit). This critical distinction ensures that submissions reach the correct payer channel, preventing unnecessary denials and delays.

Can Klivira help with Mohs surgery prior authorizations?

Yes, Klivira specifically addresses the high volume of Mohs micrographic surgery prior authorizations. Our platform validates submissions against AAD Appropriate Use Criteria, ensuring that the documented site, tumor type, and other clinical details meet payer policy requirements for platforms like Cohere Health.

How does Klivira integrate with our existing EMR for dermatology PA?

Klivira offers robust EMR integration capabilities, including SMART on FHIR and other standard interfaces. This allows for the automated extraction of relevant patient data—such as PASI, EASI, and BSA scores, as well as treatment history—directly from your EMR to populate prior authorization requests for Cohere Health and other payers.